[Comparison of the Effectiveness and Safety of Combined Chemotherapy with PEG-Asp for Treatment of ALL and T-NHL Patients].

Abstract

OBJECTIVE:

To explore the effectiveness and safety of combined chemotherapy with pegasparaginase (PEG-Asp) for treatment of patients with acute lymphoblastic leukemia (ALL) and T cell non-Hodgkin's lymphoma (T-NHL) patients.

METHODS:

A total of 62 ALL or T-NHL patients were diagnosed and treated in our department and were enrolled in this study. Among them, 22 patients received the combined chemotherapy with PEG-Asp, while the other 40 patients received the standard chemotherapy with L-asparaginase (L-Asp) as the control. Therapeutic effectiveness, adverse effects, duration and expense of hospitalization, treatment-related mortality and survival were evaluated and compared in 2 different groups.

RESULTS:

In group of combined chemotherapy with PEG-Asp, the overall response rate was 90.91% (20 cases), among them CR rate and PR rate are 77.27% (17 cases) and 13.64% (3 cases), respectively. In the group of standard chemotherapy with L-Asp, the overall response rate was 87.5% (35 cases), among them CR rate and PR rate were 72.5% (29 cases) and 15% (6 cases), respectively. The difference neither between PEG-Asp and L-Asp chemotherapy groups nor between ALL and T-NHL subgroups was significant (P > 0.05). The 6-month and 12-month overall survival rates were not significantly different between the PEG-Asp and L-Asp chemotherapy groups, respectively (P > 0.05). The adverse effects were identified as degree 1-2 according to the WHO criteria of drug toxicity. Neither the adverse effects identified as degree 3-4 nor the treatment-related death were observed. Expect for allergy and hyperglycaemia, the difference of side-effect incidence between the two groups were not significant (P > 0.05). The treatment for all the patients in PEG-Asp chemotherapy group was completed, while the treatment with L-Asp was completed only in 29 cases. Moreover, both average duration and expense of hospitalization after the combined chemotherapy were less than the control.

CONCLUSION:

With higher response rate, lower drug toxicity and allergy incidence, the combined chemotherapy with PEG-Asp can replace the standard chemotherapy with L-Asp in the treatment of ALL and T-NHL. The optimization of the combined chemotheropeutic protocols for more cases and long-term survival rates need to further and deeply explorate.

• Authors: Yan Xu, Jin Wang, Nan Yang, Ju Bai, Peng-Yu Zhang, Liu-Fang Gu, Bo Lei, Jie Liu, Fang-Xia Wang, Bing-Qiao Huang, Wang-Gang Zhang, Ai-Li He, Xing-Mei Cao, Yin-Xia Chen, Xiao-Rong Ma
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 24 Issue 2 Pg. 405-10 (Apr 2016) ISSN: 1009-2137 [Print] China
• PMID: 27151000 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Polyethylene Glycols
• pegaspargase
• Asparaginase

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Asparaginase (therapeutic use)
• Humans
• Lymphoma, T-Cell (drug therapy)
• Polyethylene Glycols (therapeutic use)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)
• Survival Rate